ABSTRACT
1. Chronic use of Saint John's wort (SJW) has been shown to lower the bioavailability for a variety of co-administered drugs including indinavir, cyclosporin, and digoxin. Decreases in intestinal absorption through induction of the multidrug resistance transporter, P-glycoprotein (P-gp), may explain decreased bioavailability. 2. The present study characterized the response of P-gp to chronic and acute exposure of SJW and hypericin (HYP, a presumed active moiety within SJW) in an in vitro system. Experiments were performed with 3 to 300 microg ml(-1) of methanol-extracted SJW and 0.03 to 3 microM HYP, representing low to high estimates of intestinal concentrations. 3. In induction experiments, LS-180 intestinal carcinoma cells were exposed for 3 days to SJW, HYP, vehicle or a positive control (ritonavir). P-gp was quantified using Western blot analysis. P-gp expression was strongly induced by SJW (400% increase at 300 microg ml(-1)) and by HYP (700% at 3 microM) in a dose-dependent fashion. Cells chronically treated with SJW had decreased accumulation of rhodamine 123, a P-gp substrate, that was reversed with acute verapamil, a P-gp inhibitor. Fluorescence microscopy of intact cells validated these findings. In Caco-2 cell monolayers, SJW and HYP caused moderate inhibition of P-gp-attributed transport at the maximum concentrations tested. 4. SJW and HYP significantly induced P-gp expression at low, clinically relevant concentrations. Similar effects occurring in vivo may explain the decreased bioavailability of P-gp substrate drugs when co-administered with SJW.
Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/biosynthesis , Hypericum , Perylene/analogs & derivatives , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Anthracenes , Antidepressive Agents/administration & dosage , Antidepressive Agents/pharmacology , Biological Transport, Active/drug effects , Blotting, Western , Caco-2 Cells , Colonic Neoplasms/metabolism , Colonic Neoplasms/pathology , Dose-Response Relationship, Drug , Drug Interactions , Drug Resistance, Multiple , Humans , Hypericum/metabolism , Image Processing, Computer-Assisted , Microscopy, Fluorescence , Perylene/administration & dosage , Perylene/pharmacology , Protein Kinase C/antagonists & inhibitors , Rhodamine 123/metabolism , Ritonavir/pharmacology , Time Factors , Tumor Cells, Cultured , Verapamil/pharmacologyABSTRACT
The relative contribution of cytochrome P450 3A (CYP3A) to the oral clearance of amitriptyline in humans has been assessed using a combination of in vitro approaches together with a clinical pharmacokinetic interaction study using the CYP3A-selective inhibitor ketoconazole. Lymphoblast-expressed CYPs were used to study amitriptyline N-demethylation and E-10 hydroxylation in vitro. The relative activity factor (RAF) approach was used to predict the relative contribution of each CYP isoform to the net hepatic intrinsic clearance (sum of N-demethylation and E-10 hydroxylation). Assuming no extrahepatic metabolism, the model-predicted contribution of CYP3A to net intrinsic clearance should equal the fractional decrement in apparent oral clearance of amitriptyline upon complete inhibition of the enzyme. This hypothesis was tested in a clinical study of amitriptyline (50 mg, p.o.) with ketoconazole (three 200 mg doses spaced 12 hours apart) in 8 healthy volunteers. The RAF approach predicted CYP2C19 to be the dominant contributor (34%), with a mean 21% contribution of CYP3A (range: 8%-42% in a panel of 12 human livers). The mean apparent oral clearance of amitriptyline in 8 human volunteers was decreased from 2791 ml/min in the control condition to 2069 ml/min with ketoconazole. The average 21% decrement (range: 2%-40%) was identical to the mean value predicted in vitro using the RAF approach. The central nervous system (CNS) sedative effects of amitriptyline were slightly greater when ketoconazole was coadministered, but the differences were not statistically significant. In conclusion, CYP3A plays a relatively minor role in amitriptyline clearance in vivo, which is consistent with in vitro predictions using the RAF approach.
Subject(s)
Amitriptyline/pharmacokinetics , Antidepressive Agents, Tricyclic/pharmacokinetics , Aryl Hydrocarbon Hydroxylases , Cytochrome P-450 Enzyme System/metabolism , Mixed Function Oxygenases/metabolism , Oxidoreductases, N-Demethylating/metabolism , Adult , Amitriptyline/blood , Antidepressive Agents, Tricyclic/blood , Antifungal Agents/blood , Antifungal Agents/pharmacokinetics , Cytochrome P-450 CYP3A , Cytochrome P-450 Enzyme System/genetics , Double-Blind Method , Drug Interactions/genetics , Female , Humans , Isoenzymes/metabolism , Ketoconazole/blood , Ketoconazole/pharmacokinetics , Male , Metabolic Clearance Rate/genetics , Microsomes, Liver/enzymology , Middle Aged , Mixed Function Oxygenases/genetics , Nortriptyline/blood , Nortriptyline/pharmacokinetics , Oxidoreductases, N-Demethylating/genetics , PhenotypeABSTRACT
The purpose of the study was to evaluate children's perceptions of their participation as research subjects in a minimal risk research study (a methylphenidate population pharmacokinetic study conducted 8 months earlier). We identified 115 children of an original 189, aged 6 to 19 years, who were responding well to regular methylphenidate for attention-deficit hyperactivity disorder. By using a structured format, telephone interviewers unconnected to the original study questioned the children about what it had been like to be a subject in terms of voluntariness, accuracy of informed consent, reasons for participating, and satisfaction with their experience. Children overwhelmingly perceived their involvement as voluntary (89%) and the information about the study as accurately presented (80%), and they reported a high level of satisfaction with their participation (97%). Self-interest was the most frequently reported reason for participation (47%). In a subsample of 25 children, the percentage of agreement of a 1-week test-retest equaled or exceeded 72% for all answers.
Subject(s)
Attention Deficit Disorder with Hyperactivity/blood , Attitude to Health , Human Experimentation , Informed Consent , Methylphenidate/pharmacokinetics , Motivation , Self Concept , Adolescent , Adult , Attention Deficit Disorder with Hyperactivity/drug therapy , Child , Clinical Trials as Topic , Female , Human Experimentation/legislation & jurisprudence , Humans , Male , Methylphenidate/blood , Methylphenidate/therapeutic use , Practice Guidelines as Topic , Retrospective Studies , United StatesABSTRACT
Transformation of escitalopram (S-CT), the pharmacologically active S-enantiometer of citalopram, to S-desmethyl-CT (S-DCT), and of S-DCT to S-didesmethyl-CT (S-DDCT), was studied in human liver microsomes and in expressed cytochromes (CYPs). Biotransformation of the R-enantiomer (R-CT) was studied in parallel. S-CT was transformed to S-DCT by CYP2C19 (K(m) = 69 microM), CYP2D6 (K(m) = 29 microM), and CYP3A4 (K(m) = 588 microM). After normalization for hepatic abundance, relative contributions to net intrinsic clearance were 37% for CYP2C19, 28% for CYP2D6, and 35% for CYP3A4. At 10 microM S-CT in liver microsomes, S-DCT formation was reduced to 60% of control by 1 microM ketoconazole, and to 80 to 85% of control by 5 microM quinidine or 25 microM omeprazole. S-DDCT was formed from S-DCT only by CYP2D6; incomplete inhibition by quinidine in liver microsomes indicated participation of a non-CYP pathway. Based on established index reactions, S-CT and S-DCT were negligible inhibitors (IC(50) > 100 microM) of CYP1A2, -2C9, -2C19, -2E1, and -3A, and weakly inhibited CYP2D6 (IC(50) = 70-80 microM). R-CT and its metabolites, studied using the same procedures, had properties very similar to those of the corresponding S-enantiomers. Thus S-CT, biotransformed by three CYP isoforms in parallel, is unlikely to be affected by drug interactions or genetic polymorphisms. S-CT and S-DCT are also unlikely to cause clinically important drug interactions via CYP inhibition.
Subject(s)
Citalopram/metabolism , Citalopram/pharmacology , Cytochromes/metabolism , Microsomes, Liver/enzymology , Selective Serotonin Reuptake Inhibitors/metabolism , Selective Serotonin Reuptake Inhibitors/pharmacology , Algorithms , Biotransformation , Humans , In Vitro Techniques , Isomerism , Kinetics , Lymphocyte Activation/drug effects , Microsomes, Liver/drug effects , TransfectionABSTRACT
To assess pharmacodynamic and neurochemical aspects of tolerance, lorazepam (2 mg/kg/day), or vehicle was administered chronically to male Crl: CD-1(ICR)BR mice via implantable osmotic pump. Open-field behavior, benzodiazepine receptor binding in vitro, receptor autoradiography, and muscimol-stimulated chloride uptake were examined at both 1 and 14 days. Open-field activity was depressed in lorazepam-treated animals on Day 1. On Day 14, open-field parameters were indistinguishable from those of vehicle-treated animals, indicating behavioral tolerance. Benzodiazepine binding, as determined by the specific binding of [125I]diazepam, was also decreased in cortex on Day 14. Hippocampal binding was unchanged following chronic lorazepam exposure. Apparent affinity in cortical membrane preparations was unchanged, indicating that altered ligand uptake was due to decreased receptor number. Muscimol-stimulated chloride uptake into cortical synaptoneurosomes from lorazepam-treated animals was not significantly different on Day 1 or Day 14 compared to vehicle-treated animals. These results confirm that down-regulation of benzodiazepine receptor binding is closely associated with behavioral tolerance to benzodiazepines. These observed changes in binding are not necessarily associated with robust changes in receptor function.
Subject(s)
Anti-Anxiety Agents/pharmacology , Behavior, Animal/drug effects , Lorazepam/pharmacology , Lorazepam/pharmacokinetics , Receptors, GABA-A/drug effects , Animals , Autoradiography , Brain/drug effects , Brain/metabolism , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Chlorides/metabolism , Diazepam/metabolism , Flunitrazepam/pharmacokinetics , GABA Agonists/pharmacology , Male , Mice , Mice, Inbred ICR , Motor Activity/drug effects , Muscimol/pharmacologyABSTRACT
The Tufts Addiction Research Center Inventory--Morphine Benzedrine Group (ARCI-MBG) scale was designed to measure benzodiazepine-induced mood elevation. The reliability and validity of the Tufts ARCI-MBG scale were determined in 64 subjects with a history of alcoholism (HA), a positive history of parental alcoholism, defined as one or both parents meeting DSM-III-R criteria for alcohol dependence (PHP), and matched control subjects. Significant correlations were found for within-day Tufts ARCI-MBG scale scores for all groups and for between-day scores for PHP and matched control subjects. Interitem reliability was significant for pooled baseline scores. For HA subjects, correlations between mean Tufts ARCI-MBG scale and Drug Liking scores that were obtained after either alprazolam or diazepam administration were significant. These results suggest that the Tufts ARCI-MBG scale is a reliable test that is a valid measure of benzodiazepine-induced mood elevation.
Subject(s)
Affect/drug effects , Alcoholism/diagnosis , Alcoholism/psychology , Benzodiazepines/adverse effects , Child of Impaired Parents , Parents/psychology , Substance-Related Disorders/diagnosis , Substance-Related Disorders/psychology , Surveys and Questionnaires , Adult , Alcoholism/epidemiology , Child , Female , Humans , Male , Psychiatric Status Rating Scales , Reproducibility of ResultsABSTRACT
The capacity of three clinically available nonnucleoside reverse transcriptase inhibitors (NNRTIs) to inhibit the activity of human cytochromes P450 (CYPs) was studied in vitro using human liver microsomes. Delavirdine, nevirapine, and efavirenz produced negligible inhibition of phenacetin O-deethylation (CYP1A2) or dextromethorphan O-demethylation (CYP2D6). Nevirapine did not inhibit hydroxylation of tolbutamide (CYP2C9) or S-mephenytoin (CYP2C19), but these CYP isoforms were importantly inhibited by delavirdine and efavirenz. This indicates the likelihood of significantly impaired clearance of CYP2C substrate drugs (such as phenytoin, tolbutamide, and warfarin) upon initial exposure to these two NNRTIs. Delavirdine and efavirenz (but not nevirapine) also were strong inhibitors of CYP3A, consistent with clinical hazards of initial cotreatment with either of these drugs and substrates of CYP3A. The in vitro microsomal model provides relevant predictive data on probable drug interactions with NNRTIs when the mechanism is inhibition of CYP-mediated drug biotransformation. However, the model does not incorporate interactions attributable to enzyme induction.
Subject(s)
Anti-HIV Agents/pharmacology , Cytochrome P-450 Enzyme Inhibitors , Reverse Transcriptase Inhibitors/pharmacology , Alkynes , Benzoxazines , Cyclopropanes , Cytochrome P-450 Enzyme System/metabolism , Delavirdine/pharmacology , Humans , Hydrolysis , Inhibitory Concentration 50 , Isoenzymes/antagonists & inhibitors , Isoenzymes/metabolism , Microsomes, Liver/drug effects , Microsomes, Liver/enzymology , Nevirapine/pharmacology , Oxazines/pharmacology , Triazolam/metabolismABSTRACT
Since antiretroviral drugs are known to inhibit many cytochrome P450 isoforms, the inhibition of CYP2B6 by non-nucleoside reverse transcriptase inhibitors and viral protease inhibitors was studied in vitro in human liver microsomes using bupropion hydroxylation as the CYP2B6 index reaction. Mean IC(50) values (microM) for inhibition of bupropion hydroxylation were: nelfinavir (2.5), ritonavir (2.2), and efavirenz (5.5). The reaction was only weakly inhibited by indinavir, saquinavir, amprenavir, delavirdine, and nevirapine. The inhibition of bupropion hydroxylation in vitro by nelfinavir, ritonavir, and efavirenz indicates inhibitory potency versus CYP2B6 and suggests the potential for clinical drug interactions.
Subject(s)
Anti-HIV Agents/pharmacology , Antidepressive Agents, Second-Generation/metabolism , Aryl Hydrocarbon Hydroxylases , Bupropion/metabolism , Cytochrome P-450 Enzyme Inhibitors , HIV Protease Inhibitors/pharmacology , Oxidoreductases, N-Demethylating/antagonists & inhibitors , Reverse Transcriptase Inhibitors/pharmacology , Alkynes , Antidepressive Agents, Second-Generation/pharmacology , Benzoxazines , Bupropion/pharmacology , Cyclopropanes , Cytochrome P-450 CYP2B6 , Cytochrome P-450 Enzyme System/metabolism , Drug Interactions , Humans , Hydroxylation , Inhibitory Concentration 50 , Microsomes, Liver/drug effects , Microsomes, Liver/enzymology , Nelfinavir/pharmacology , Oxazines/pharmacology , Oxidoreductases, N-Demethylating/metabolism , Ritonavir/pharmacologyABSTRACT
The kinetics of flunitrazepam (FNTZ) N-demethylation to desmethylflunitrazepam (DM FNTZ), and 3-hydroxylation to 3-hydroxyflunitrazepam (3-OH FNTZ), were studied in human liver microsomes and in microsomes containing heterologously expressed individual human CYPs. FNTZ was N-demethylated by cDNA-expressed CYP2A6 (K(m) = 1921 microM), CYP2B6 (K(m) = 101 microM), CYP2C9 (K(m) = 50 microM), CYP2C19 (K(m) = 60 microM), and CYP3A4 (K(m) = 155 microM), and 3-hydroxylated by cDNA-expressed CYP2A6 (K(m) = 298 microM) and CYP3A4 (K(m) = 286 microM). The 3-hydroxylation pathway was predominant in liver microsomes, accounting for more than 80% of intrinsic clearance compared with the N-demethylation pathway. After adjusting for estimated relative abundance, CYP3A accounted for the majority of intrinsic clearance via both pathways. This finding was supported by chemical inhibition studies in human liver microsomes. Formation of 3-OH FNTZ was reduced to 10% or less of control values by ketoconazole (IC(50) = 0.11 microM) and ritonavir (IC(50) = 0.041 microM). Formation of DM FNTZ was inhibited to 40% of control velocity by 2.5 microM ketoconazole and to 30% of control by 2.5 microM ritonavir. Neither 3-OH FNTZ nor DM FNTZ formation was inhibited to less than 85% of control activity by alpha-naphthoflavone (CYP1A2), sulfaphenazole (CYP2C9), omeprazole (CYP2C19), or quinidine (CYP2D6). Thus, CYP-dependent FNTZ biotransformation, like that of many benzodiazepine derivatives, is mediated mainly by CYP3A. Clinical interactions of FNTZ with CYP3A inhibitors can be anticipated.
Subject(s)
Anti-Anxiety Agents/metabolism , Cytochrome P-450 Enzyme System/metabolism , Flunitrazepam/analogs & derivatives , Flunitrazepam/metabolism , Mixed Function Oxygenases/metabolism , Benzoflavones/pharmacology , Cytochrome P-450 CYP3A , Cytochrome P-450 Enzyme Inhibitors , Cytochrome P-450 Enzyme System/genetics , Enzyme Inhibitors/pharmacology , Humans , Hydroxylation , Isoenzymes/antagonists & inhibitors , Isoenzymes/genetics , Isoenzymes/metabolism , Ketoconazole/pharmacology , Kinetics , Methylation , Microsomes, Liver/enzymology , Microsomes, Liver/metabolism , Mixed Function Oxygenases/antagonists & inhibitors , Mixed Function Oxygenases/genetics , Omeprazole/pharmacology , Quinidine/pharmacology , Ritonavir/pharmacology , Sulfaphenazole/pharmacology , TransfectionABSTRACT
The metabolism of the antidepressant mirtazapine (MIR) was investigated in vitro using human liver microsomes (HLM) and recombinant enzymes. Mean K(m) values (+/-S.D., n = 4) were 136 (+/-44) microM for MIR-hydroxylation, 242 (+/-34) microM for N-demethylation, and 570 (+/-281) microM for N-oxidation in HLM. Based on the K(m) and V(max) values, MIR-8-hydroxylation, N-demethylation, and N-oxidation contributed 55, 35, and 10%, respectively, to MIR biotransformation in HLM at an anticipated in vivo liver MIR concentration of 2 microM. Recombinant CYP predicted a 65% contribution of CYP2D6 to MIR-hydroxylation at 2 microM MIR, decreasing to 20% at 250 microM. CYP1A2 contribution increased correspondingly from 30 to 50%. In HLM, quinidine and alpha-naphthoflavone reduced MIR-hydroxylation to 75 and 45% of control, respectively, at 250 microM MIR. A >50% contribution of CYP3A4 to MIR-N-demethylation at <1 microM MIR was indicated by recombinant enzymes. In HLM, ketoconazole (1 microM) reduced N-desmethylmirtazapine formation rates to 60% of control at 250 microM. Twenty percent of MIR-N-oxidation was accounted for by CYP3A4 at 2 microM MIR, increasing to 85% at 250 microM, while CYP1A2 contribution decreased from 80 to 15%. Ketoconazole reduced MIR-N-oxidation to 50% of control at 250 microM. MIR did not substantially inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP1E2, and CYP3A4 activity in vitro. Induction/inhibition or genetic polymorphisms of CYP2D6, CYP1A2, and CYP3A4 may affect MIR metabolism, but involvement of several enzymes in different metabolic pathways may prevent large alterations in in vivo drug clearance.
Subject(s)
Antidepressive Agents, Tricyclic/metabolism , Mianserin/analogs & derivatives , Mianserin/metabolism , Antidepressive Agents, Tricyclic/pharmacology , Benzoflavones/pharmacology , Cytochrome P-450 Enzyme Inhibitors , Cytochrome P-450 Enzyme System/genetics , Cytochrome P-450 Enzyme System/metabolism , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Humans , Hydroxylation/drug effects , Isoenzymes/antagonists & inhibitors , Isoenzymes/genetics , Isoenzymes/metabolism , Methylation/drug effects , Mianserin/pharmacology , Microsomes, Liver/drug effects , Microsomes, Liver/metabolism , Mirtazapine , Oxidation-Reduction/drug effects , Quinidine/pharmacology , Recombinant Proteins/antagonists & inhibitors , Recombinant Proteins/metabolismABSTRACT
The in vitro biotransformation of bupropion to hydroxybupropion was studied in human liver microsomes and microsomes containing heterologously expressed human cytochromes P450 (CYP). The mean (+/-S.E.) K(m) in four human liver microsomes was 89 (+/-14) microM. In microsomes containing cDNA-expressed CYPs, hydroxybupropion formation was mediated only by CYP2B6 at 50 microM bupropion (K(m) 85 microM). A CYP2B6 inhibitory antibody produced more than 95% inhibition of bupropion hydroxylation in four human livers. Bupropion hydroxylation activity at 250 microM was highly correlated with S-mephenytoin N-demethylation activity (yielding nirvanol), another CYP2B6-mediated reaction, in a panel of 32 human livers (r = 0.94). The CYP2B6 content of 12 human livers highly correlated with bupropion hydroxylation activity (r = 0.96). Thus bupropion hydroxylation is mediated almost exclusively by CYP2B6 and can serve as an index reaction reflecting activity of this isoform. IC(50) values for inhibition of a CYP2D6 index reaction (dextromethorphan O-demethylation) by bupropion and hydroxybupropion were 58 and 74 microM, respectively. This suggests a low inhibitory potency versus CYP2D6, the clinical importance of which is not established. Since bupropion is frequently coadministered with other antidepressants, IC(50) values (microM) for inhibition of bupropion hydroxylation were determined as follows: paroxetine (1.6), fluvoxamine (6.1), sertraline (3.2), desmethylsertraline (19.9), fluoxetine (59.5), norfluoxetine (4.2), and nefazodone (25.4). Bupropion hydroxylation was only weakly inhibited by venlafaxine, O-desmethylvenlafaxine, citalopram, and desmethylcitalopram. The inhibition of bupropion hydroxylation in vitro by a number of newer antidepressants suggests the potential for clinical drug interactions.
Subject(s)
Antidepressive Agents, Second-Generation/metabolism , Aryl Hydrocarbon Hydroxylases , Bupropion/metabolism , Cytochrome P-450 Enzyme System/metabolism , Fluoxetine/analogs & derivatives , Oxidoreductases, N-Demethylating/metabolism , Sertraline/analogs & derivatives , Antibodies/pharmacology , Antidepressive Agents, Second-Generation/pharmacokinetics , Biotransformation , Bupropion/pharmacokinetics , Chromatography, High Pressure Liquid , Cytochrome P-450 CYP2B6 , Cytochrome P-450 Enzyme System/immunology , Dose-Response Relationship, Drug , Drug Interactions , Fluoxetine/pharmacology , Fluvoxamine/pharmacology , Humans , Hydroxylation/drug effects , Isoenzymes/metabolism , Kinetics , Microsomes, Liver/metabolism , Oxidoreductases, N-Demethylating/immunology , Paroxetine/pharmacology , Piperazines , Sertraline/pharmacology , Triazoles/pharmacologyABSTRACT
BACKGROUND: The viral protease inhibitor ritonavir has the capacity to inhibit and induce the activity of cytochrome P450-3A (CYP3A) isoforms, leading to drug interactions that may influence the efficacy and toxicity of other antiretroviral therapies, as well as pharmacologic treatments of coincident or complicating diseases. METHODS: The inhibitory effect of ritonavir on the biotransformation of the hypnotic agents triazolam and zolpidem was tested in vitro using human liver microsomes. In a double-blind clinical study, volunteer study subjects received 0.125 mg triazolam or 5.0 mg zolpidem concurrent with low-dose ritonavir (four doses of 200 mg), or with placebo. RESULTS: Ritonavir was a potent in vitro inhibitor of triazolam hydroxylation but was less potent as an inhibitor of zolpidem hydroxylation. In the clinical study, ritonavir reduced triazolam clearance to < 4% of control values (p < .005), prolonged elimination half-life (41 versus 3 hours; p < .005), and magnified benzodiazepine agonist effects such as sedation and performance impairment. In contrast, ritonavir reduced zolpidem clearance to 78% of control values (p < .08), and slightly prolonged elimination half-life (2.4 versus 2.0 hours; NS). Benzodiazepine agonist effects of zolpidem were not altered by ritonavir. CONCLUSION: Short-term low-dose administration of ritonavir produces a large and significant impairment of triazolam clearance and enhancement of clinical effects. In contrast, ritonavir produced small and clinically unimportant reductions in zolpidem clearance. The findings are consistent with the complete dependence of triazolam clearance on CYP3A activity, compared with the partial dependence of zolpidem clearance on CYP3A.
Subject(s)
Anti-Anxiety Agents/pharmacokinetics , Aryl Hydrocarbon Hydroxylases , HIV Protease Inhibitors/pharmacology , Hypnotics and Sedatives/pharmacokinetics , Pyridines/pharmacokinetics , Ritonavir/pharmacology , Triazolam/pharmacokinetics , Adult , Anti-Anxiety Agents/blood , Cytochrome P-450 CYP3A , Cytochrome P-450 Enzyme Inhibitors , Double-Blind Method , HIV Seronegativity , Half-Life , Humans , Hypnotics and Sedatives/blood , Male , Metabolic Clearance Rate/drug effects , Oxidoreductases, N-Demethylating/antagonists & inhibitors , Pyridines/blood , Triazolam/blood , ZolpidemABSTRACT
OBJECTIVE: To evaluate the kinetics and dynamics of lorazepam during administration as a bolus plus an infusion, using electroencephalography as a pharmacodynamic end point. METHODS: Nine volunteers received a 2-mg bolus loading dose of lorazepam, coincident with the start of a 2 microg/kg/hr zero-order infusion. The infusion was stopped after 4 hrs. Plasma lorazepam concentrations and electroencephalographic activity in the 13- to 30-Hz range were monitored for 24 hrs. RESULTS: The bolus-plus-infusion scheme rapidly produced plasma lorazepam concentrations that were close to those predicted to be achieved at true steady state. Mean kinetic values for lorazepam were as follows: volume of distribution, 126 L; elimination half-life, 13.8 hrs; and clearance, 109 mL/min. Electroencephalographic effects were maximal 0.5 hr after the loading dose, were maintained essentially constant during infusion, and then declined in parallel with plasma concentrations after the infusion was terminated. There was no evidence of tolerance. Plots of pharmacodynamic electroencephalographic effect vs. plasma lorazepam concentration demonstrated counterclockwise hysteresis, consistent with an effect-site equilibration delay. This was incorporated into a kinetic-dynamic model in which hypothetical effect-site concentration was related to pharmacodynamic electroencephalographic effect via the sigmoid Emax model. The analysis yielded the following mean estimates: maximum electroencephalographic effect, 12.7% over baseline; 50% effective concentration, 13.1 ng/mL; and effect-site equilibration half-life, 8.8 mins. CONCLUSION: Despite the delay in effect onset, continuous infusion of lorazepam, preceded by a bolus loading dose, produces a relatively constant sedative effect on the central nervous system, which can be utilized in the context of critical care medicine.
Subject(s)
Hypnotics and Sedatives/pharmacokinetics , Lorazepam/pharmacokinetics , Adult , Electroencephalography , Humans , Hypnotics and Sedatives/administration & dosage , Infusions, Intravenous , Lorazepam/administration & dosage , Male , Middle AgedABSTRACT
The pharmacokinetics and pharmacodynamics of the benzodiazepine alprazolam (1 mg, administered orally) were compared between eight patients with panic disorder and eight age- and sex-matched healthy volunteers. Subjects received orally administered placebo and alprazolam in a randomized, double-blind, single-dose crossover study. The elimination half-life, time of maximum plasma concentration, maximum concentration, volume of distribution, and clearance of alprazolam were similar for both groups. For each cohort, alprazolam treatment (vs. placebo) produced significant changes in typical benzodiazepine agonist effects, such as increased sedation and impaired cognitive performance on the digit-symbol substitution test. For the panic disorder group only, there was a significant increase in the subjective rating of"contented" and a reduction in the rating of "easily irritated." For the healthy volunteer group, alprazolam produced increases in ratings of "fatigued" and "slowed thinking," but also increases in ratings of "relaxed." In each group, alprazolam significantly increased the electroencephalographic (EEG) measure of relative beta amplitude (range, 13-30 Hz) compared with placebo. Concentration-EEG response curves fit a sigmoid E(max) model, and there was greater sensitivity to EEG effects, as measured by a 28% reduction in the EC50 value, in the panic disorder group compared with healthy control subjects. After alprazolam treatment, there was increased sensitivity to EEG and mood effects and fewer aversive effects in the panic disorder group compared with healthy subjects. There were no differences in the pharmacodynamic measures of sedation and cognition or differences in pharmacokinetics between the two groups.
Subject(s)
Alprazolam/pharmacology , Alprazolam/pharmacokinetics , Anti-Anxiety Agents/pharmacology , Anti-Anxiety Agents/pharmacokinetics , Panic Disorder/drug therapy , Adult , Alprazolam/therapeutic use , Anti-Anxiety Agents/therapeutic use , Cross-Over Studies , Double-Blind Method , Electroencephalography/drug effects , Female , Half-Life , Humans , Male , Panic Disorder/psychology , Psychiatric Status Rating Scales , Time FactorsABSTRACT
BACKGROUND: Pharmacokinetic interactions involving antiretroviral therapies may critically influence the efficacy and toxicity of these drugs, as well as pharmacologic treatments of coincident or complicating diseases. The viral protease inhibitor ritonavir is of particular concern since it both inhibits and induces the activity of cytochrome P450 3A (CYP3A) isoforms. METHODS: The inhibitory effect of ritonavir on the metabolism of alprazolam, a CYP3A-mediated reaction in humans, was tested in vitro using human liver microsomes. In a double-blind clinical study, volunteer subjects received 1.0 mg of alprazolam concurrent with low-dose ritonavir (four doses of 200 mg) or with placebo. RESULTS: Ritonavir was a potent in vitro inhibitor of alprazolam hydroxylation. The 50% inhibitory concentration was 0.11 micromol/L (0.08 microg/mL); this is below the usual therapeutic plasma concentration range (generally exceeding 2 microg/mL). In the clinical study, ritonavir reduced alprazolam clearance to 41% of control values (P < .001), prolonged elimination half-life (mean values, 30 versus 13 hours; P < .005), and magnified benzodiazepine agonist effects such as sedation and performance impairment. CONCLUSION: Consistent with in vitro results, administration of low doses of ritonavir for a short duration of time resulted in large impairment of alprazolam clearance and enhancement of clinical effects. Removal from product labeling of a warning against coadministration of ritonavir and alprazolam was based on a previous study only of extended exposure to ritonavir, in which CYP3A induction offset inhibition. Kinetic interactions involving antiretroviral therapies may be complex and time dependent. Product labeling should reflect this complexity.
Subject(s)
Alprazolam/metabolism , Anti-Anxiety Agents/metabolism , Aryl Hydrocarbon Hydroxylases , HIV Protease Inhibitors/pharmacology , Microsomes, Liver/drug effects , Microsomes, Liver/metabolism , Ritonavir/pharmacology , Adult , Alprazolam/blood , Alprazolam/pharmacokinetics , Anti-Anxiety Agents/blood , Anti-Anxiety Agents/pharmacokinetics , Antifungal Agents/pharmacology , Cytochrome P-450 CYP3A , Cytochrome P-450 Enzyme System/drug effects , Double-Blind Method , Drug Interactions , Drug Labeling , Female , HIV Protease Inhibitors/blood , Humans , Hydroxylation/drug effects , Ketoconazole/pharmacology , Male , Metabolic Clearance Rate , Oxidoreductases, N-Demethylating/drug effects , Protein Isoforms/drug effects , Ritonavir/bloodSubject(s)
Contraceptives, Oral/pharmacokinetics , Cytochrome P-450 Enzyme System/biosynthesis , Drug Interactions , Mixed Function Oxygenases/biosynthesis , Contraceptives, Oral/administration & dosage , Contraceptives, Oral/adverse effects , Cytochrome P-450 CYP3A , Enzyme Induction/drug effects , Female , Humans , Infant, Newborn , Metabolic Clearance Rate/drug effects , Pregnancy , Risk FactorsABSTRACT
Eighteen healthy volunteers (10 men and 8 women) participated in a single-dose, double-blind, three-way crossover pharmacokinetic and pharmacodynamic study. Treatment conditions were 0.25 mg of triazolam, a full-agonist benzodiazepine ligand; 10 mg of zolpidem, an imidazopyridine having relative selectivity for the type 1 benzodiazepine receptor subtype; and placebo. Weight-normalized clearance of triazolam was higher in women than in men (8.7 versus 5. 5 ml/min/kg), but the difference was not significant. In contrast, zolpidem clearance was lower in women than in men (3.5 versus 6.7 ml/min/kg, P <.06). Compared to placebo, both active medications produced significant benzodiazepine agonist-like pharmacodynamic effects: sedation, impaired psychomotor performance, impaired information recall, and increased electroencephalographic beta-amplitude. Effects of triazolam and zolpidem in general were comparable and less than 8 h in duration. There was no evidence of a substantial or consistent sex difference in pharmacodynamic effects or in the kinetic-dynamic relationship, although subtle differences could not be ruled out due to low statistical power. The complete dependence of triazolam clearance on CYP3A activity, as opposed to the mixed CYP participation in zolpidem clearance, may explain the differing sex effects on clearance of the two compounds.